SCHEMBL3205134

SCHEMBL3205134

CCCN(C)CCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 10/20 0.61
KDM5A P29375 8/20 0.61
KDM5C P41229 1/20 0.52
KDM5B Q9UGL1 1/20 0.52
PHF8 Q9UPP1 3/20 0.50
KDM4A O75164 2/20 0.50
FFAR3 O14843 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
AKR1B1 P15121 1/20 0.44
KDM7A Q6ZMT4 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
PPARG P37231 4/20 0.42
PPARD Q03181 4/20 0.42
PPARA Q07869 4/20 0.42
TSHR P16473 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL3412852 0.90 FFAR3 (0.65) KDM4CKDM5AKDM5CKDM5BPHF8
SCHEMBL718216 0.89 KMT2A (0.56) KDM4CKDM5AKDM5CKDM5BPHF8
Methane SCHEMBL15776806 0.87 KMT2A (0.54) KDM4CKDM5AKDM5CKDM5BPHF8
SCHEMBL11239382 0.87 KMT2A (0.54) KDM4CKDM5AKDM5CKDM5BPHF8
SCHEMBL5525490 0.86 KDM4C (0.70) KDM4CKDM5AKDM5CKDM5BPHF8
SCHEMBL15745412 0.86 KDM4C (0.62) KDM4CKDM5AKDM5CKDM5BPHF8
Valeric Acid SCHEMBL3410743 0.86 AKR1B1 (0.58) KDM4CKDM5AKDM5CKDM5BPHF8
Propionic Acid SCHEMBL3412690 0.84 FFAR3 (0.56) KDM4CKDM5AKDM5CKDM5BPHF8
Hexanoate SCHEMBL3416214 0.84 AKR1B1 (0.70) KDM4CKDM5AKDM5CKDM5BPHF8
SCHEMBL11584728 0.84 KDM4C (0.68) KDM4CKDM5AKDM5CKDM5BPHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984754-B1 Aliphatic amino carboxylic and amino phosphonic acids amino nitriles and amino tetrazoles as cellular rescue agents UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) 2006-01-10 US claimed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-10025011-B2 Composition, infrared transmission filter and method for manufacturing the same, and infrared sensor FUJIFILM CORPORATION (JP) 2018-07-17 US disclosed
US-9810821-B2 Infrared ray cutoff filter FUJIFILM CORPORATION (JP) 2017-11-07 US disclosed
US-20170237114-A1 ALL-SOLID-STATE SECONDARY BATTERY, SOLID ELECTROLYTE COMPOSITION AND ELECTRODE SHEET FOR BATTERIES USED IN THE SAME, AND MANUFACTURING METHOD OF ELECTRODE SHEET FOR BATTERIES AND ALL-SOLID-STATE SECONDARY BATTERY FUJIFILM CORPORATION (JP) 2017-08-17 US disclosed
US-9632222-B2 Method for manufacturing a color filter, color filter and solid-state imaging device FUJIFILM CORPORATION (JP) 2017-04-25 US disclosed
US-9507257-B2 Method for manufacturing a color filter, color filter and solid-state imaging device FUJIFILM CORPORATION (JP) 2016-11-29 US disclosed
US-9442373-B2 Method of producing color filter and solid-state imaging device having colored composition containing color agent FUJIFILM CORPORATION (JP) 2016-09-13 US disclosed
US-9442374-B2 Coloring composition, method for manufacturing a color filter using the same, color filter and solid-state imaging device FUJIFILM CORPORATION (JP) 2016-09-13 US disclosed
US-20160033680-A1 COMPOSITION FOR FORMING FAR-INFRARED RADIATION SHIELDING LAYER FUJIFILM CORPORATION (JP) 2016-02-04 US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 EP disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 EP disclosed
EP-0866705-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-03-03 EP disclosed
EP-0866705-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-09-30 EP disclosed
WO-1997014417-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-04-24 WO disclosed
EP-0252505-B1 1-HYDROXY-3-(N-METHYL-N-PROPYL AMINO)PROPANE-1,1-DIPHOSPHONIC ACID, PROCESS FOR ITS PREPARATION AND MEDICINES CONTAINING THIS COMPOUND Roche Diagnostics GmbH (DE) 1992-09-16 EP disclosed
US-4942157-A CALCIUM METABOLISM, BONE DISORDERS BOEHRINGER MANNHEIM GMBH (DE) 1990-07-17 US disclosed
WO-1988000590-A1 DIPHOSPHONIUM ACID DERIVATES AND MEDICINES CONTAINING THE SAME BOEHRINGER MANNHEIM GMBH (DE) 1988-01-28 WO disclosed
EP-0252505-A1 1-Hydroxy-3-(N-methyl-N-propyl amino)propane-1,1-diphosphonic acid, process for its preparation and medicines containing this compound Roche Diagnostics GmbH (DE) 1988-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 KDM4C 4349/4885KDM5A 4278/4885KDM5C 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.